Menu Search
Equities

Abionyx Pharma SA

609:FRA

Abionyx Pharma SA

Actions
  • Price (EUR)1.31
  • Today's Change0.028 / 2.19%
  • Shares traded2.00k
  • 1 Year change+12.56%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

  • Revenue in EUR (TTM)4.86m
  • Net income in EUR-3.36m
  • Incorporated2005
  • Employees61.00
  • Location
    Abionyx Pharma SABat. D 33-43 Avenue Georges PompidouBALMA 31130FranceFRA
  • Phone+33 562249706
  • Fax+33 562190417
  • Websitehttps://www.abionyx.com/en/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.